Altimmune Stock News

Wall Street analysts forecast that Altimmune, Inc. (NASDAQ:ALT) will post earnings per share of ($0.62) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Altimmunes earnings, with the lowest EPS estimate coming in at ($0.89) and the highest estimate coming in at ($0.36). Altimmune reported earnings of ($0.17) per share []

Vanguard Group Inc. raised its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 19.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,586,093 shares of the companys stock after buying an additional 258,883 shares during the quarter. Vanguard Group Inc. owned []

Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2021 Results - Earnings Call Transcript

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Altimmune has been one of the top-performing stocks in our speculative portfolio. The company recently reported encouraging results from their NASH candidate, ALT-801. The market has been bullish on A

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised t

GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting v

New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors ar

GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on it

H.C. Wainwright said that Altimmune Inc (NASDAQ:ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients.  However, shares dropped, which he sees primar

Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.

The stock price of Altimmune Inc (NASDAQ: ALT) fell by over 19% during intraday trading today. This is why it happened.

Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.

Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. At 12 week

GAITHERSBURG, Md., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemv